HEM

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

Bidgely Secures $26M in Financing to Accelerate Utilities’ Leading Role in the Clean Energy Future

Tuesday, September 14, 2021 - 12:00pm

The oversubscribed round also included existing investors, such as Future Energy Ventures, Georgian and Constellation Technology Ventures.

Key Points: 
  • The oversubscribed round also included existing investors, such as Future Energy Ventures, Georgian and Constellation Technology Ventures.
  • Bidgely partners with nearly 40 global utilities and energy retailers to glean valuable customer energy insights using data from smart meters already installed in the home.
  • Bidgely CEO Abhay Gupta commented, Adding new strategic and experienced investors to our roster renews our mission to be the clean energy accelerator for utilities.
  • Bidgely is an AI-powered SaaS Company accelerating a clean energy future by enabling energy companies and consumers to make data-driven energy-related decisions.